- Find a clinical trial
- MS9140001_0002
Colorectal
MS9140001_0002 (PROCEADE-CRC-03)
A randomized, open-label, 3-arm Phase III study of precemtabart tocentecan as single agent or in combination with bevacizumab compared to trifluridine/tipiracil plus bevacizumab in participants with previously treated metastatic colorectal cancer (PROCEADE-CRC-03).
Trial overview
Medical Oncology
Colorectal
Gastrointestinal (GI)
III
Registration number: NCT07549412
St Leonards (North Shore Health Hub)
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
Madhawa De Silva
Medical Oncologist
··
··
Thank you for submitting.
Thank you for submitting.
We will be in touch within 24 hours
Form submission error
An unexpected error has occurred.
You will need to complete the form again, sorry for the inconvenience.
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.
You are leaving our website
You are now leaving our website. GenesisCare do not control this content and therefore are not responsible for its accuracy or reliability.